|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
187.28
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27372. [Epub ahead of print] Review. PubMed PMID: 29570866.
2: Riederer P, Müller T. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. J Neural Transm (Vienna). 2018 Mar 22. doi: 10.1007/s00702-018-1876-2. [Epub ahead of print] Review. PubMed PMID: 29569037.
3: Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3:CD000208. doi: 10.1002/14651858.CD000208.pub2. Review. PubMed PMID: 29552749.
4: Szökő É, Tábi T, Riederer P, Vécsei L, Magyar K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. J Neural Transm (Vienna). 2018 Feb 7. doi: 10.1007/s00702-018-1853-9. [Epub ahead of print] Review. PubMed PMID: 29417334.
5: Naoi M, Maruyama W, Shamoto-Nagai M. Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons. J Neural Transm (Vienna). 2017 Dec 26. doi: 10.1007/s00702-017-1832-6. [Epub ahead of print] Review. PubMed PMID: 29279995.
6: Ramsay RR, Tipton KF. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Molecules. 2017 Jul 15;22(7). pii: E1192. doi: 10.3390/molecules22071192. Review. PubMed PMID: 28714881.
7: Nagy Z, Nardai S. Cerebral ischemia/repefusion injury: From bench space to bedside. Brain Res Bull. 2017 Sep;134:30-37. doi: 10.1016/j.brainresbull.2017.06.011. Epub 2017 Jun 15. Review. PubMed PMID: 28625785.
8: Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci. 2017 Mar 4;18(3). pii: E551. doi: 10.3390/ijms18030551. Review. PubMed PMID: 28273839; PubMed Central PMCID: PMC5372567.
9: Dezsi L, Vecsei L. Monoamine Oxidase B Inhibitors in Parkinson's Disease. CNS Neurol Disord Drug Targets. 2017;16(4):425-439. doi: 10.2174/1871527316666170124165222. Review. PubMed PMID: 28124620.
10: Riederer P, Müller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):233-240. doi: 10.1080/17425255.2017.1273901. Epub 2017 Jan 1. Review. PubMed PMID: 27998194.
11: Finberg JP, Rabey JM. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Front Pharmacol. 2016 Oct 18;7:340. eCollection 2016. Review. PubMed PMID: 27803666; PubMed Central PMCID: PMC5067815.
12: Miklya I. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Mol Psychiatry. 2016 Nov;21(11):1499-1503. doi: 10.1038/mp.2016.127. Epub 2016 Aug 2. Review. PubMed PMID: 27480491.
13: Saka C. An Overview of Analytical Methods for the Determination of Monoamine Oxidase Inhibitors in Pharmaceutical Formulations and Biological Fluids. Crit Rev Anal Chem. 2017 Jan 2;47(1):1-23. Epub 2016 Oct 7. Review. PubMed PMID: 27715253.
14: Castells X, Cunill R, Pérez-Mañá C, Vidal X, Capellà D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380. doi: 10.1002/14651858.CD007380.pub4. Review. PubMed PMID: 27670244.
15: Laver K, Dyer S, Whitehead C, Clemson L, Crotty M. Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open. 2016 Apr 27;6(4):e010767. doi: 10.1136/bmjopen-2015-010767. Review. Erratum in: BMJ Open. 2017 Jun 7;7(5):e010767corr1. PubMed PMID: 27121704; PubMed Central PMCID: PMC4854009.
16: Magalhães PV, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016 Feb 5;2:CD008919. doi: 10.1002/14651858.CD008919.pub2. Review. PubMed PMID: 26848926.
17: Cristancho MA, Thase ME. Critical appraisal of selegiline transdermal system for major depressive disorder. Expert Opin Drug Deliv. 2016;13(5):659-65. doi: 10.1517/17425247.2016.1140145. Epub 2016 Feb 19. Review. PubMed PMID: 26837935.
18: Márquez-Cruz M, Díaz-Martínez JP, Soto-Molina H, De Saráchaga AJ, Cervantes-Arriaga A, Llorens-Arenas R, Rodríguez-Violante M. A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):97-102. doi: 10.1586/14737167.2016.1135740. Epub 2016 Jan 25. Review. PubMed PMID: 26731410.
19: Zhang LL, Canning SD, Wang XP. Freezing of Gait in Parkinsonism and its Potential Drug Treatment. Curr Neuropharmacol. 2016;14(4):302-6. Review. PubMed PMID: 26635194; PubMed Central PMCID: PMC4876585.
20: Bied AM, Kim J, Schwartz TL. A critical appraisal of the selegiline transdermal system for major depressive disorder. Expert Rev Clin Pharmacol. 2015;8(6):673-81. doi: 10.1586/17512433.2016.1093416. Epub 2015 Oct 1. Review. Erratum in: Expert Rev Clin Pharmacol. 2016;9(2):339. PubMed PMID: 26427518.
